Business
Update On Board Investigation and Interims Date
SkinBioTherapeutics plc expects its shares to be suspended from trading on April 1, 2026, due to a delay in publishing its interim results for the six months ended December 31, 2025, which are contingent on an ongoing Board investigation. The company reported a robust cash position of £2.44 million as of March 19, 2026, and its businesses are operating as usual. Trading is anticipated to resume once the investigation concludes and the interim results are released. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n \n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\" or the \"Group\")\n \nUpdate On Board Investigation, Interim Results\nand Expected Suspension of Trading\n \n· HY26 results to be delayed until Board Investigation is complete\n· Shares expected to be suspended from 1 April 2026 until HY26 results are published\n \n20 March 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, updates shareholders on the timing for the interim results for the 6 months ended 31 December 2025 (\"Interim Results\") and the ongoing Board investigation.\n \nAs announced on 20 February 2026, the Board appointed FRP Advisory to undertake an independent, forensic review into the matters outlined by the Company on Monday 16 February 2026. Whilst progress is being made, this forensic review is ongoing and accordingly, the Company will not be in a position to announce the Interim Results by 31 March 2026, as required by the AIM Rules for Companies.\n \nConsequently, the Board expects that trading in the Company's ordinary shares will be suspended with effect from 7.30am on 1 April 2026. Trading in the shares is anticipated to resume upon the finalisation of the Board investigation and the publication of the Interim Results.\n \nThe Company has a robust cash position of £2.44m as at the close of 19 March 2026 and its businesses are trading on a \"business as usual\" basis.\n \nThe Board will update shareholders on the result of the forensic review and Board investigation as soon as possible.\n \nThis announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"MAR\"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.\n \n-Ends-\nFor more information please contact:\n\n\n\n\nSkinBioTherapeutics plc Martin Hunt, Executive Chairman\nRachel Parsonage, Interim CEO\nEmily Bertram, CFO\n\n\[email protected]\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\nPhilip Davies\nJames Todd\nPatrick Weaver\n\n\n+44 (0) 020 7496 3000\n \n\n\n\n\nVigo Consulting Melanie Toyne...